• ABOUT
  • TEAM
  • SERVICES
  • RESULTS
  • MEDIA & EVENTS

Celon Pharma has positively concluded the decentralised procedure (DCP) for Salmex® on Scandinavian markets

by plexusventures_h3tnl0 | Nov 30, 2017 | Uncategorized

Plexus Ventures would like to share successful news from Celon Pharma. Additional details are provided in Celon’s press release (Warsaw, 30.11.2017): • Finalisation of the DCP opens new perspectives for the Company in terms of export to the market as big as approx. 3...

Plexus Ventures Assists Celon Pharma SA with Development Strategy

by plexusventures_h3tnl0 | Aug 17, 2017 | Uncategorized

Philadelphia, PA – Plexus Ventures, a global pharmaceutical consulting firm, announces its collaboration with Celon Pharma SA, Łomianki, Poland. Michael O’Sullivan Managing Partner London Office, noted: “We are very pleased to provide continuing support to an...

Plexus Ventures Assists Sylphar with Vendis Capital Investment, Enabling Concordia Fund Exit

by plexusventures_h3tnl0 | Jun 13, 2017 | Uncategorized

Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce it assisted the successful completion of a transaction in which Vendis Capital, a European private equity fund specialized in the consumer brands sector, invested in Sylphar, a fast-growing,...

Fujifilm Kyowa Kirin Biologics Announces EMA Acceptance to Review Biosimilar FKB327

by plexusventures_h3tnl0 | May 22, 2017 | Uncategorized

Philadelphia, PA – Plexus Ventures is pleased to announce that its client, Fujifilm Kyowa Kirin Biologics (FKB), has confirmed that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application for FKB327 (adalimumab biosimilar)....
« Older Entries
Next Entries »

Recent Posts

  • Plexus Ventures Assists First Pharma in Successful Completion of Business Sale to a Strategic Buyer
  • Plexus Ventures Assists Sanofi Consumer Health to Divest a Product Portfolio in Australia and South-East Asia to Phoenix Labs
  • Plexus Ventures Assists Elthera AG in the Licensing of its First-in-Class Antibody
  • Celon Pharma enters agreement with Zydus Lifesciences Ltd.
  • Mindpax engages Plexus Ventures as Exclusive Advisor to Partner its Digital Platform for Severe Mental Illnesses

Recent Comments

    Collaborating with clients to grow their businesses; committing our experience, resources and time to their success.

    Business Builders in Healthcare

    Contact Us
    • Follow

    About Us

    Our Team

    Areas of Expertise

    Project Portfolio

    What’s Trending